Press release
Obesity Market Size was around ~USD 2000 Million (US) in 2023, estimated DelveInsight
Discover Key Insights into the Obesity Market with DelveInsight's In-Depth Report @ Obesity Market Size [https://www.delveinsight.com/sample-request/weight-loss-weight-management-obesity-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Obesity Market Report
* In November 2024:- Carmot Therapeutics Inc.- A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Phase 2 Study to Evaluate the Efficacy, Safety, and Tolerability of Once-Weekly CT-388 Administered Subcutaneously for 48 Weeks to Participants Who Are Overweight or Obese with Type 2 Diabetes Mellitus. This is a multi-center, randomized, double-blind, placebo-controlled, parallel group dose-finding study to evaluate the efficacy and safety of CT-388 at low, middle, and high doses in participants who are overweight or obese with Type 2 diabetes mellitus (T2DM).
* In November 2024:- Eli Lilly and Company- A Phase 3, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Retatrutide Compared to Tirzepatide in Adults Who Have Obesity. The main purpose of this study is to evaluate the efficacy and safety of retatrutide compared to tirzepatide in adults who have obesity. The study will last about 89 weeks.
* As per DelveInsight's estimates, the United States accounted for the highest number of total prevalent cases of Obesity among the 7 MM in 2023.
* DelveInsight's consultant estimates that adult patients constituted the maximum number of cases of obesity patients seeking help in 2023.
* According to the findings, treatment rate for children was found to be less than that of adults across countries.
* Among EU4 and the UK, the highest number of treated cases of obesity in adults was observed in the United Kingdom in 2023, which is followed by Germany.
* The leading Obesity Companies such as Rhythm Pharmaceuticals, Boehringer Ingelhium, D&D Pharmatech, ProQR Therapeutics, Nano Precision Medical, Bukwang Pharmaceutical, Caliway Biopharmaceutics, Yuhan, Terns Pharmaceuticals, BioRestorative Therapies, SCOHIA PHARMA, Click Therapeutics, Hanmi Pharmaceuticals, Novo Nordisk, Empros Pharma, Carmot Therapeutics, Eli Lilly and Company, and others
* Promising Obesity Therapies such as IMCIVREE (setmelanotide), ZEPBOUND (tirzepatide), Semaglutide oral, Survodutide (BI 456906), DD03, AX-0601, NPM 139, BK-1701, CBW-520, YH34160, TERN-601, Thermostem, SCO-267, CT-181, HM15136, NNC0480-0389, EMP-16, CT-868, Semaglutide , and others
Stay ahead in the Obesity Therapeutics Market with DelveInsight's Strategic Report @ Obesity Market Outlook [https://www.delveinsight.com/sample-request/weight-loss-weight-management-obesity-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Obesity Epidemiology Segmentation in the 7MM
* Total Prevalence of Obesity
* Prevalent Cases of Obesity by severity
* Gender-specific Prevalence of Obesity
* Diagnosed Cases of Episodic and Chronic Obesity
Download the report to understand which factors are driving Obesity epidemiology trends @ Obesity Prevalence [https://www.delveinsight.com/sample-request/weight-loss-weight-management-obesity-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Marketed Obesity Drugs
* IMCIVREE (setmelanotide): Rhythm Pharmaceuticals
Imcivree is a melanocortin 4 (MC4) receptor agonist indicated for chronic weight management in adult and pediatric patients 6 years of age and older with obesity. In November 2020, Rhythm Pharmaceuticals announced the US FDA approval of Imcivree as the first-ever therapy for chronic weight management in patients with obesity due to POMC, PCSK1, or LEPR deficiency. Earlier, in May 2017, FDA expanded the Breakthrough Therapy Designation to disorders involving genetic defects upstream of the melanocortin-4 receptor in the leptin-melanocortin pathway.
* ZEPBOUND (tirzepatide): Eli Lilly and Company
Tirzepatide is a once-weekly glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist that integrates the actions of both incretins into a single novel molecule. In November 2023, the US FDA approved Eli Lilly and Company's ZEPBOUND (tirzepatide) injection, the first obesity treatment of its kind that activates both GIP and GLP-1 hormone receptors. ZEPBOUND is indicated for adults with obesity (with a BMI of 30 kg/m2 or greater), or those who are overweight (with a BMI of 27 kg/m2 or greater) and also have weight-related medical problems such as hypertension, dyslipidemia, Type II diabetes mellitus, obstructive sleep apnea or cardiovascular disease, to lose weight and keep it off.
Emerging Obesity Drugs
* Semaglutide oral: Novo Nordisk
Oral semaglutide is approved as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes in the US, EU and Japan under the trade name, RYBELSUS. It is an oral GLP-1 RA, an analogue of the naturally occurring hormone GLP-1. Currently, the company is developing the candidate for obesity. The candidate is being evaluated in various Phase III trials (OASIS 1, OASIS 2, OASIS 3 and OASIS 4) to assess the safety and efficacy of the drug in subjects with overweight or obesity.
* Survodutide (BI 456906): Boehringer Ingelhium
Survodutide (BI 456906) is a GCGR/GLP1 dual agonist being developed by Boehringer Ingelhium. GLP1 agonism is expected to lower body weight and provide glucose control. Both receptors are critical to controlling metabolic functions. The compound leverages the known effects of the natural gut hormone oxyntomodulin, which has been shown to decrease food intake and increase energy expenditure in humans as well as the established effects of GLP1 agonism on both glucose control and body weight. The dual agonist BI 456906 has potential as a new, once-weekly treatment that may offer therapeutically relevant benefits compared to currently available treatments.
Get In-Depth Knowledge on Obesity Market Trends and Forecasts with DelveInsight @ Obesity Treatment Market [https://www.delveinsight.com/sample-request/weight-loss-weight-management-obesity-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Obesity Market Report
* Coverage- 7MM
* Obesity Companies- Rhythm Pharmaceuticals, Boehringer Ingelhium, D&D Pharmatech, ProQR Therapeutics, Nano Precision Medical, Bukwang Pharmaceutical, Caliway Biopharmaceutics, Yuhan, Terns Pharmaceuticals, BioRestorative Therapies, SCOHIA PHARMA, Click Therapeutics, Hanmi Pharmaceuticals, Novo Nordisk, Empros Pharma, Carmot Therapeutics, Eli Lilly and Company, and others
* Obesity Therapies- IMCIVREE (setmelanotide), ZEPBOUND (tirzepatide), Semaglutide oral, Survodutide (BI 456906), DD03, AX-0601, NPM 139, BK-1701, CBW-520, YH34160, TERN-601, Thermostem, SCO-267, CT-181, HM15136, NNC0480-0389, EMP-16, CT-868, Semaglutide, and others.
* Obesity Therapeutic Assessment: Obesity Current marketed and Obesity Emerging Therapies
* Obesity Market Dynamics: Obesity Market drivers and Obesity Market Barriers
Unlock Strategic Insights with DelveInsight's Comprehensive Obesity Market Report @ Obesity Market Drivers and Barriers [https://www.delveinsight.com/sample-request/weight-loss-weight-management-obesity-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Contents
1. Key Insights
2. Report Introduction
3. Obesity Market Overview at a Glance
4. Executive Summary
5. Key Events
6. Epidemiology and Market Methodology
7. Disease Background and Overview
8. Epidemiology and Patient Population
9. Japan Epidemiology Scenario
10. Patient Journey
11. Marketed Therapies
12. Emerging Therapies
13. Obesity Market: The 7MM Analysis
14. Obesity Market Access and Reimbursement
15. KOL Views
16. SWOT Analysis
17. Unmet Needs
18. Appendix
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=obesity-market-size-was-around-usd-2000-million-us-in-2023-estimated-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/case-study/respiratory-domain-conference-coverage
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Obesity Market Size was around ~USD 2000 Million (US) in 2023, estimated DelveInsight here
News-ID: 3767146 • Views: …
More Releases from ABNewswire
Leavitt Peak Press Announces the Release of the Guardians: Paporia Two by F. Tho …
Leavitt Peak Press is proud to announce the release of The Guardians: Paporia Two, the action-packed sequel to The Guardians: Escape from Tirgonia by military veteran and author F. Thomas Jones. This thrilling continuation of the Guardians saga dives deeper into a galactic conflict that pits courage, loyalty, and wisdom against overwhelming odds.
Now in the second year of war with the ruthless Tirogian Empire, The Guardians face their greatest challenge…
Jiaropack Expands Global Footprint and U.S. Manufacturing to Strengthen Supply C …
Image: https://www.abnewswire.com/upload/2025/10/e8885cfe8ab28873224866f01a36a3fa.jpg
California, USA - Jiaropack, a brand of Global Store Supply, Inc., a global leader in packaging, industrial, and shipping materials, today announced a major expansion of its U.S. manufacturing and logistics network to further enhance supply chain stability and nationwide delivery efficiency, providing faster and more reliable products and services to customers worldwide.
To enhance supply chain security and consistent product delivery, Jiaropack has recently purchased several Texas-based plastic product…
Clostridioides Difficile Infection Market Size in the 7MM was ~USD 500 million i …
DelveInsight's "Clostridioides Difficile Infection Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of the Clostridioides Difficile Infection, historical and forecasted epidemiology as well as the Clostridioides Difficile Infection therapeutics market trends in the US, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
Discover Key Insights into the Clostridioides Difficile Infection Market with DelveInsight's In-Depth Report @ Clostridioides Difficile Infection Treatment Market Size…
Triple Negative Breast Cancer Market Set for Robust Growth Through 2034Innovativ …
Driven by rise of immunotherapies, antibody-drug conjugates, and precision-targeted approaches, TNBC market is projected to expand from USD 4.7 billion in 2025 to USD 7.1 billion by 2034, marking a CAGR of 4.7% across the 7MM. Leading players like AstraZeneca, Pfizer, Gilead Sciences, BioNTech, Astellas Pharma are at forefront, advancing next-generation therapies such as ADC platforms, checkpoint inhibitors, and novel vaccines that aim to improve survival outcomes and redefine patient…
More Releases for Obesity
Anti-Obesity Drugs Market Grows Rapidly, Driven by Obesity Rates and Therapeutic …
Anti-Obesity Drugs Market valued at USD 5.9 Bn in 2024, growing at 16.5% CAGR to reach USD 20.02 Bn by 2032. Driven by GLP-1 therapies and rising obesity rates.
Anti Obesity Drugs Market Overview:
The anti-obesity drugs market is undergoing significant transformation as awareness about obesity-related health risks rises globally. With growing concern over lifestyle-related disorders, there is an increasing emphasis on medical intervention as a complement to traditional weight management strategies.…
Fuzzle joins The Obesity Society & The Obesity Action Coalition; Promotes Habit- …
Building healthy, sustainable habits for long-term weight management success.
Tampa, FL - March 18, 2025 - Fuzzle, an emerging leader in the wellness landscape, is pleased to announce that it's now a Member of The Obesity Society, as well as the Obesity Action Coalition, marking a new milestone in the company's mission to transform how individuals approach weight loss.
Image: https://www.globalnewslines.com/uploads/2025/03/77da787ae98a633847c70fc22e2943c7.jpg
Fuzzle supports individuals in their wellness journey through non-invasive, drug-free strategies. With…
Pediatric Obesity Management Market - Healthy Habits for Life: Advancing Pediatr …
Newark, New Castle, USA: The "Pediatric Obesity Management Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors.
Pediatric Obesity Management Market: https://www.growthplusreports.com/report/pediatric-obesity-management-market/8930
This latest report researches the industry structure,…
Anti-Obesity Drugs Market - From Obesity to Vitality: Leading the Way in Effecti …
Newark, New Castle, USA - new report, titled Anti-Obesity Drugs Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Anti-Obesity Drugs market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Anti-Obesity Drugs market. The report offers an overview of the market, which…
Increasing Prevalence of Obesity Driving Obesity/Bariatric Surgery Devices Marke …
The global obesity/bariatric surgery devices market revenue stood at $1.4 billion in 2016, and it is expected to rise to $2.8 billion by 2023. Furthermore, the market will progress at a CAGR of 9.9% from 2017 to 2023 (forecast period), as per the estimates of the market research company, P&S Intelligence. The major growth drivers of the market are the rising incidence of obesity, owing to unhealthy diets and lifestyle…
Fast Food and Obesity
Most of the fast food in the market contains a large quantity of sugar, #carbs and fats with a lesser quantity of vitamins and minerals. The unhealthy food ingredients in the fast food are further increased with increased portion size. The person will still consume the whole meal regardless of being completely full. People cannot stop ravishing on fast food because it is available for low cost and in close…
